Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

There are multiple chapters near you. Select your preferred chapter.

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

ROCKVILLE, MD, USA I 16, 2024 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN ...